4DMT un­veils dose ex­plo­ration da­ta in wet AMD; Ex­i­cure in­stalls new C-suite ex­ec

4D Mol­e­c­u­lar Ther­a­peu­tics has some new da­ta from a Phase I/II tri­al test­ing a wet AMD can­di­date in dif­fer­ent dose lev­els.

The biotech re­port­ed Thurs­day in­ter­im da­ta from three dos­es of ge­net­ic med­i­cine can­di­date 4D-150 in 15 pa­tients, de­liv­ered in­trav­it­re­al­ly. Be­yond all the dos­es be­ing well-tol­er­at­ed, 4D said that all three dos­es showed “clin­i­cal ac­tiv­i­ty,” which in­clud­ed met­rics such as sta­ble vi­su­al acu­ity and “sta­ble or im­proved reti­nal ede­ma and thick­ness.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER